These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 33560877)

  • 1. Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial.
    Kanemitsu Y; Shitara K; Mizusawa J; Hamaguchi T; Shida D; Komori K; Ikeda S; Ojima H; Ike H; Shiomi A; Watanabe J; Takii Y; Yamaguchi T; Katsumata K; Ito M; Okuda J; Hyakudomi R; Shimada Y; Katayama H; Fukuda H;
    J Clin Oncol; 2021 Apr; 39(10):1098-1107. PubMed ID: 33560877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.
    Lin Q; Ding K; Zhao R; Wang H; Wei Y; Ren L; Ye Q; Cui Y; He G; Tang W; Feng Q; Zhu D; Chang W; Wang X; Liang L; Zhou G; Liang F; Ye F; Wang J; Fan J; Xu J
    Eur J Cancer; 2023 Sep; 191():112961. PubMed ID: 37473466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases.
    Niitsu H; Hinoi T; Shimomura M; Egi H; Hattori M; Ishizaki Y; Adachi T; Saito Y; Miguchi M; Sawada H; Kochi M; Mukai S; Ohdan H
    World J Surg Oncol; 2015 Apr; 13():162. PubMed ID: 25908502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
    Kim MS; Chung M; Ahn JB; Kim CW; Cho MS; Shin SJ; Baek SJ; Hur H; Min BS; Baik SH; Kim NK
    J Surg Oncol; 2014 Aug; 110(2):214-21. PubMed ID: 24668581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
    Tang W; Ren L; Liu T; Ye Q; Wei Y; He G; Lin Q; Wang X; Wang M; Liang F; Cui Y; Xu J
    J Clin Oncol; 2020 Sep; 38(27):3175-3184. PubMed ID: 32749938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study).
    Moritani K; Kanemitsu Y; Shida D; Shitara K; Mizusawa J; Katayama H; Hamaguchi T; Shimada Y;
    Jpn J Clin Oncol; 2020 Jan; 50(1):89-93. PubMed ID: 31829404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials.
    Rahbari NN; Biondo S; Frago R; Feißt M; Kreisler E; Rossion I; Serrano M; Jäger D; Lehmann M; Sommer F; Dignass A; Bolling C; Vogel I; Bork U; Büchler MW; Folprecht G; Kieser M; Lordick F; Weitz J;
    J Clin Oncol; 2024 May; 42(13):1531-1541. PubMed ID: 38412408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of primary tumor resection for asymptomatic colorectal cancer patients with unresectable metastases: a systematic review and meta-analysis.
    Li S; Ji L; Huang J; Wang Y; Liu P; Zhang W; Lou Z
    Int J Colorectal Dis; 2023 Aug; 38(1):214. PubMed ID: 37581775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial.
    Kim CW; Baek JH; Choi GS; Yu CS; Kang SB; Park WC; Lee BH; Kim HR; Oh JH; Kim JH; Jeong SY; Ahn JB; Baik SH
    Trials; 2016 Jan; 17():34. PubMed ID: 26782254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
    Yamazaki K; Nagase M; Tamagawa H; Ueda S; Tamura T; Murata K; Eguchi Nakajima T; Baba E; Tsuda M; Moriwaki T; Esaki T; Tsuji Y; Muro K; Taira K; Denda T; Funai S; Shinozaki K; Yamashita H; Sugimoto N; Okuno T; Nishina T; Umeki M; Kurimoto T; Takayama T; Tsuji A; Yoshida M; Hosokawa A; Shibata Y; Suyama K; Okabe M; Suzuki K; Seki N; Kawakami K; Sato M; Fujikawa K; Hirashima T; Shimura T; Taku K; Otsuji T; Tamura F; Shinozaki E; Nakashima K; Hara H; Tsushima T; Ando M; Morita S; Boku N; Hyodo I
    Ann Oncol; 2016 Aug; 27(8):1539-46. PubMed ID: 27177863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Avallone A; Piccirillo MC; Nasti G; Rosati G; Carlomagno C; Di Gennaro E; Romano C; Tatangelo F; Granata V; Cassata A; Silvestro L; De Stefano A; Aloj L; Vicario V; Nappi A; Leone A; Bilancia D; Arenare L; Petrillo A; Lastoria S; Gallo C; Botti G; Delrio P; Izzo F; Perrone F; Budillon A
    JAMA Netw Open; 2021 Jul; 4(7):e2118475. PubMed ID: 34309665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
    Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of primary tumor resection in patients with stage IV colorectal cancer with unresectable metastases.
    Urvay S; Eren T; Civelek B; Kilickap S; Yetiysigit T; Ozaslan E
    J BUON; 2020; 25(2):939-944. PubMed ID: 32521889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial.
    van der Kruijssen DEW; Elias SG; Vink GR; van Rooijen KL; 't Lam-Boer J; Mol L; Punt CJA; de Wilt JHW; Koopman M;
    JAMA Surg; 2021 Dec; 156(12):1093-1101. PubMed ID: 34613339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
    Yamada Y; Denda T; Gamoh M; Iwanaga I; Yuki S; Shimodaira H; Nakamura M; Yamaguchi T; Ohori H; Kobayashi K; Tsuda M; Kobayashi Y; Miyamoto Y; Kotake M; Shimada K; Sato A; Morita S; Takahashi S; Komatsu Y; Ishioka C
    Ann Oncol; 2018 Mar; 29(3):624-631. PubMed ID: 29293874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcome of primary tumor resection in the unresectable stage IV colorectal cancer patients who received the bevacizumab-containing chemotherapy.
    Yeom SS; Lee SY; Kwak HD; Kim CH; Kim YJ; Kim HR
    Medicine (Baltimore); 2020 Feb; 99(7):e19258. PubMed ID: 32049866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.